Recent Updates
Recently added Catalysts
NEOG Positive Sentiment

Neogen Launches Enhanced Genomic Test for Cats Neogen® Corporation (NASDAQ: NEOG) announced today that it has launched My CatScan™ 2.0, a significantly upgraded and improved version of the test...

Key Takeaway: Neogen Corporation has announced the launch of My CatScan™ 2.0, an upgraded genetic screening test for cats. This new version includes 39 additional diseases and genetic traits, bringing the total to over 120 health conditions that can be screened. The test utilizes a noninvasive cheek swab method, aimed at providing valuable insights for cat owners, breeders, and veterinarians about feline health and well-being. My CatScan 2.0 is now available for purchase online.
Price reaction · baseline $19.09 (2023-06-12 close) · hit after-hours · clean, no other NEOG news in the window
day 0 close · peak
+3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Launch of My CatScan 2.0 significantly upgrades feline genetic testing.
  • New test includes 39 additional diseases and genetic traits.
  • Test designed to provide a hassle-free experience for cat owners.

Full Press Release Details

LINCOLN, Neb. , June 13, 2023 /PRNewswire/ -- Neogen® Corporation (NASDAQ: NEOG ) announced today that it has launched My CatScan™ 2.0, a significantly upgraded and improved version of the test from a leader in genetic screening for cats.
With the addition of 39 new diseases and genetic traits, My CatScan 2.0 is the latest genetic screening designed exclusively for cats, now offering information on more than 120 genetic health conditions. The test is designed to be a hassle-free experience for both feline companions and owners, utilizing a simple, noninvasive cheek swab method.
"At Neogen, we are committed to revolutionizing feline health through comprehensive genomic screening," said Dr. Robert Westra , Associate Medical Director at Neogen. "With the expanded analysis provided by My CatScan 2.0, we provide cat parents, feline breeders, and veterinarians with a greater depth of knowledge to provide insights about the health and well-being of their feline companions."
Every cat, regardless of age or breed, can benefit from a deeper understanding of their genetic health. Genetic testing provides a number of advantages for cat owners, breeders, and veterinarians alike, including:
My CatScan 2.0 is now available for purchase via www.mycatscan.com . For more information, please contact Neogen's customer success team at [email protected] or call 509.483.5950.
Neogen Corporation develops and markets comprehensive solutions dedicated to food and animal safety, operating with the intention to "Every day, protect the people and animals we care about." The Company's Food Safety segment markets dehydrated culture media and diagnostic test kits to detect foodborne bacteria, natural toxins, food allergens, drug residues, plant diseases, and sanitation concerns. Neogen's Animal Safety segment is a leader in the development of genomic solutions along with the manufacturing and distribution of a variety of animal healthcare products, including diagnostics, pharmaceuticals, veterinary instruments, wound care, and disinfectants, as well as rodent and insect control solutions.

Frequently Asked Questions

What is My CatScan™ 2.0?

My CatScan™ 2.0 is an advanced genetic screening test for cats, offering insights into over 120 health conditions.

How does My CatScan 2.0 collect samples?

The test uses a noninvasive cheek swab method to collect samples from cats.

How many diseases does My CatScan 2.0 test for?

It screens for 39 new diseases, totaling over 120 genetic health conditions.

Who can benefit from My CatScan 2.0?

Cat owners, breeders, and veterinarians can all gain valuable insights from the test.

Where can I purchase My CatScan 2.0?

My CatScan 2.0 is available for purchase at www.mycatscan.com.

Last updated: Jun 13, 2023